logo

Proteos Biotech

Almansa Nº 14, Bioincubadora Building, 1º floor,02006, Albacete. 

Spain. Tel: +34 915 417 000

PROTEOS BIOTECH is a leading manufacturer of enzymes for biomedical use, cell cultures and cosmetics. Our enzymes, such as collagenase, Pz-peptidase, keratinase and subtilisin are produced under recombinant conditions and purified by chromatography.

Our enzymes offer the best quality and purity standards on the market. All our enzymes are biochemically tested in vitro and in cell culture in both primary culture and cell lines. The tests are carried out by independent scientific researchers and certified companies in Europe. PROTEOS BIOTECH guarantees the best level of safety, quality and efficiency of our products.

Detailed information on our products and protocols is available on our website adapted for primary cell cultures such as hippocampus, cerebral cortex, cerebellum, liver, pancreas, heart and stem cells, among others.

Visit our wevsite: http://proteosbiotech.com/

Highlights

  • Laboratory reagents
  • Research by contract
  • Contract manufacturing
  • PBSerum Cosmeceuticals

Services

  • Full project design support
  • Flexibility to meet your needs.
  • Project transparency with meetings and follow-up reports.
  • Delivery time
  • Successful completion of your Project

Our value proposition

Research and custom development

We provide R&D services for biotechnology, pharmacy and drug discovery companies

Custom production

Custom production of biological products and peptides.

Cosmetics

New line of cosmetic PBSerum.

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.